Moderna Inc. said it will reduce annual spending by about $1.5 billion by 2027 as the company continues to cut costs to ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

Moderna on Thursday pushed back the time frame for likely approval of a combination vaccine meant to protect against both ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company's ...

Moderna (MRNA) was in focus Thursday morning after the vaccine maker announced plans to expand its cost efficiency and ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

The Cambridge-based biotech company has been trying to reduce operating expenses as it burns cash on its large pipeline.

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Vaccinations for Covid-19 are now underway in the U.S. Two vaccines – one from Pfizer and BioNTech, one from Moderna — have ...

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

On a Thursday conference call with investors, Moderna CFO Jamey Mock outlined a roadmap for the mRNA specialist to lower its ...